Clinical Trial Update: Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) [Phase 3]

View source ↗

Summary

Phase 3 trial update indicates completion of evaluating low-dose infliximab for ankylosing spondylitis (Study P04352) sponsored by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: COMPLETED